Scopus Biopharma

Scopus Biopharma Liabilities

The The Liabilities of Scopus Biopharma (SCPS) as of Nov 16, 2026 is 7.45 M USD. In the previous year, The Liabilities was 4.17 M USD — a change of 78.75% (higher).

Liabilities

7.45 MUSD

YoY

78.75%

Last updated:

In 2022, Scopus Biopharma's total liabilities amounted to 7.45 M USD, a 78.75% difference from the 4.17 M USD total liabilities in the previous year.

The Scopus Biopharma Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2017
111,282.00 USD
Jan 1, 2018
137,964.00 USD
Jan 1, 2019
854,541.00 USD
Jan 1, 2020
3.81 M USD
Jan 1, 2021
4.17 M USD
Jan 1, 2022
7.45 M USD
The Scopus Biopharma Liabilities history
YEARLiabilitiesYoY
7.45 MUSD+78.75%
4.17 MUSD+9.59%
3.81 MUSD+345.30%
854,541.00USD+519.39%
137,964.00USD+23.98%
111,282.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scopus Biopharma Stock analysis

What does Scopus Biopharma do? Scopus Biopharma Inc develops therapeutics targeting diseases with unmet medical needs, focusing on immuno-oncology programs. The company's Duet Platform utilizes bifunctional oligonucleotides to activate antigen-presenting cells and alleviate tumor immunosuppression. DUET-01 is in development for relapsed or refractory B-cell non-Hodgkin lymphoma, while DUET-02 targets solid tumors like prostate or kidney cancers through systemic delivery. The firm's products are developed for clinical trials and potential future commercialization. Scopus Biopharma's revenue streams are not disclosed in the business description, but the company is developing its Duet Platform products for potential licensing or partnership agreements. The immuno-oncology focus and bifunctional oligonucleotide platform represent the core of the company's product pipeline. The company's products target specific cancer types with unmet medical needs, aiming to jump-start T cell-mediated immune responses. The company's development pipeline includes DUET-01 for B-cell non-Hodgkin lymphoma and DUET-02 for solid tumors. The Duet Platform's three bifunctional oligonucleotides (DUET-01, DUET-02, DUET-03) form the foundation of its therapeutic approach. The firm is developing these products for potential commercialization after successful clinical trials and regulatory approvals. Scopus Biopharma is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Scopus Biopharma's Liabilities

Scopus Biopharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Scopus Biopharma's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Scopus Biopharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Scopus Biopharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Scopus Biopharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Scopus Biopharma stock

The Liabilities of Scopus Biopharma is 7.45 M USD in 2022.

The Liabilities of Scopus Biopharma changed from 4.17 M USD to 7.45 M USD, representing a 78.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Scopus Biopharma since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Scopus Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Scopus Biopharma

All Key Metrics — Scopus Biopharma